Stocks making the biggest moves midday: Intel, AMD, Charter, Hims & Hers, Eli Lilly and more

Midday trading was driven by a sharp split in earnings reactions and analyst moves, led by Intel's 23% surge after first-quarter EPS of 29 cents on $13.58 billion in revenue topped estimates and second-quarter guidance came in well above expectations. On the downside, Comcast fell nearly 8% on a Deutsche Bank downgrade, Charter dropped 23% after a 120,000 subscriber decline, and Coursera sank more than 10% after disappointing Q1 results. Healthcare names were mixed-to-negative, with Eli Lilly down nearly 4% on soft early Foundayo prescription data, HCA Healthcare off more than 7% on weaker admissions, and Organon jumping 22% on reported takeover interest.

Analysis

This tape is less about broad market direction than a sharp repricing of earnings durability versus narrative. The biggest winners are names where a single data point validated an inflection story: semis and AI infrastructure, where improved guideposts tend to cascade through the whole supply chain as allocators chase “proof” rather than probability. Intel’s beat matters less for the company itself than for the implied read-through to PC/server refresh and memory pricing, which can mechanically lift AMD, QCOM, MU, LRCX, WDC, and STX for several sessions as fast money re-scores the entire complex.

The losers cluster where the market was already paying for stability or secular growth, and the print exposed fragility in either volume or pricing power. Comcast/Charter are a cautionary signal for other cash-flow-yield telecom/adjacent names: if subscriber losses are not just cyclical, the market will start treating “defensive” businesses like ex-growth value traps, compressing multiples even if free cash flow remains intact. In healthcare, HCA’s move says utilization risk is now colliding with policy and reimbursement uncertainty; that can pressure managed-care sentiment and hospital vendors even if the near-term earnings miss is modest. Meanwhile, Eli Lilly’s selloff creates a near-term opportunity for the obesity-duopoly trade to rotate back toward incumbents if launch execution remains uneven.

The main contrarian read is that the AI/semiconductor rally may be larger than the underlying fundamental change today. A one-quarter beat does not fix end-demand; it just re-opens the funding window and short-covering channel, so the move is likely to be more durable in suppliers with actual backlog leverage than in the headline names. Separately, the soft launch in GLP-1 pills could be underappreciated as a distribution problem rather than a molecule problem, which favors existing brand leaders and channel partners over pure new-format bets over the next 1-2 quarters.

Key Decisions for Investors

• Long basket: AMD/QCOM/MU/LRCX against short the Nasdaq beta via QQQ on a 1-3 week horizon; thesis is that semis outperform the index as earnings revisions broaden after Intel, with 2:1 upside/downside if follow-through buying persists.
• Enter a pair trade: long INTC / short a basket of low-multiple software or defensive telco names over the next 2-4 weeks; risk is high because INTC has already moved sharply, but relative revision momentum can remain strong if guidance is later confirmed.
• Short CMCSA or CHTR on any bounce, 1-2 week trade; use tight risk controls because the market may initially overreact to valuation compression, but the setup favors multiple de-rating if subscriber trends remain negative.
• Buy NVO or a NVO/HIMS pair for 1-2 months; if pill launch data stabilizes, the market will likely re-rate incumbency and channel power faster than it rewards new entrants, offering better asymmetry than chasing HIMS after a sympathy move.
• Fade the HCA move with a small short or put spread into the next utilization data point; the risk/reward improves if macro reimbursement concerns stay front-and-center, but this is more of a months-long catalyst than a same-day trade.